All these data above demonstrated that CA might suppress oxidative and inflammation via AMPK-mediated keap1/Nrf2 activation and NFκB inhibition in NAFLD. The gene discussed is KEAP1; the disease is metabolic dysfunction-associated steatotic liver disease.